Search
Apremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalApremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. … [A181244,L7495] Initially approved in 2014, it is marketed by Celgene.
Mixtures: OTEZLA 10 MG. 20 MG Y 30 MG, OTEZLA 10 MG. 20 MG Y 30 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesAvelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: BAVENCIO®, BAVENCIO 200 MG/10 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 FLAKONCrotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedIt is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label]. … Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species.
Olsalazine
go.drugbank.com/drugs/DB01250ApprovedOlsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). … [A257063] Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151]
Categories: Non COX-2 selective NSAIDSVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalVibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. … [L28310] Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigationalDorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and … [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Mixtures: COSOPT S 20/5MG/ML, COSOPT S 20MG/ML+5MG/MLCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsProducts: 1 RayvowAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC
Synonyms: 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrileCategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsAntipyrine
go.drugbank.com/drugs/DB01435ApprovedAntipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Synonyms: 2,3-Dimethyl-1-phenyl-5-pyrazolone, 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-oneMixtures: CALZAS®, SUPRENIL STERIL OFTALMIK SUSPANSIYON 5 MLSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one, Kras G12C inhibitor 9